Murepavadin
CAS No. 944252-63-5
Murepavadin( POL7080 | POL 7080 )
Catalog No. M16763 CAS No. 944252-63-5
Murepavadin (POL7080) is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMurepavadin
-
NoteResearch use only, not for human use.
-
Brief DescriptionMurepavadin (POL7080) is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
-
DescriptionMurepavadin (POL7080) is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.Bacterial Infection Phase 3 Clinical.
-
In VitroMurepavadin has activity against P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L.Murepavadin inhibits megalin-mediated uptake of gentamicin in vitro with an IC50 value of 5.84 μM.
-
In VivoMurepavadin (s.c.; 0-100 mg/kg) is active in pre-clinical animal models including infections with XDR isolates. Animal Model:murine models of P. aeruginosa infectionDosage:0-100 mg/kg Administration:Subcutaneous, q24h or q12h Result:Resulted in an increase in survival rate to 100% and showed significantly lower CFU levels both in the blood and in the peritoneal fluid at 2 and 10 mg/kg 1 h post-infection.Animal Model:Mouse, rat, rabbit, and monkey Dosage:0-5 mg/kg Administration:Intraperitoneal or subcutaneous, single Result:Followed a two-compartment model following intravenous administration and decline of plasma concentrations.Distributed into the aqueous phase of the body, and systemic plasma clearance (CL) values were similar to the species-specific glomerular filtration rates (GFRs) .Had high bioavailability (67.79%) after subcutaneous (s.c.) administration in rats but had low oral bioavailability (<0.01%).Had a linear relationship between ELF AUC and unbound plasma AUC in mouse.
-
SynonymsPOL7080 | POL 7080
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research AreaInfection
-
IndicationBacterial Infection
Chemical Information
-
CAS Number944252-63-5
-
Formula Weight1553.837
-
Molecular FormulaC73H112N22O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)N3CCCC3C(=O)NC(C(=O)NC(C(=O)N1)CC4=CNC5=CC=CC=C54)C(C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
-
Chemical Namecyclo[Ala-Ser-D-Pro-Pro-Thr-Trp-Ile-Dab-Orn-D-Dab-Dab-Trp-Dab-Dab]
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
N-Acetyltyramine
N-Acetyltyramine is the active compound extracted from a fermentation broth of strain M3-10 which produces quorum-sensing inhibitor (QSI) compound. N-Acetyltyramine inhibits Chromobacterium violaceum ATCC 12472 violacein production and virulence factors, such as pyoverdine production, as well as swarming and twitching motilities, produced by Pseudomonas aeruginosa PAO1.
-
Rifaximin
Rifaximin is an oral, semi-synthetic antibiotic derived from Rifamycin SV with antibacterial activity.
-
N-(3-cyano-4,5,6,7-t...
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyrazine-2-carboxamide exhibit an inhibitory effect on bacterial DNA helicases, nucleases, or helicase-nuclease enzyme complexes, such as, for example, one or more enzymes selected from the RecBCD and AddAB families of enzymes.
Cart
sales@molnova.com